The global antibody discovery market, valued at USD 1.9 billion in 2024, is projected to reach USD 3.3 billion by 2030, with a CAGR of 9.8%. Growth is fueled by expanding pipelines in monoclonal antibodies, rapid adoption of bispecifics, and increasing investment in antibody–drug conjugates (ADCs). Advances in single B-cell technologies, AI-driven design, and stable cell line development are accelerating discovery and reducing development risks. As demand rises for next-generation biologics, AtaGenix provides integrated discovery, screening, and engineering platforms to help researchers and partners achieve faster, cost-effective progress.